Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML

Blood (2022) 139 (8): 1208–1221.

https://doi.org/10.1182/blood.2021011354

Published: 2022

Includes: Supplemental data

Journal Articles

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment

Andreas Hochhaus, Brian Druker, Charles Sawyers, Francois Guilhot, Charles A. Schiffer, Jorge Cortes, Dietger W. Niederwieser, Carlo Gambacorti-Passerini, Richard M. Stone, John Goldman, Thomas Fischer, Stephen G. O'Brien, Jose J. Reiffers, Manisha Mone, Tillmann Krahnke, Moshe Talpaz, Hagop M. Kantarjian

Blood (2008) 111 (3): 1039–1043.

https://doi.org/10.1182/blood-2007-07-103523

Published: 2008

Journal Articles

An MMR Control RNA for Reliable Monitoring of BCR-ABL Transcripts in Treated CML Patients.

Julie Toplin, Courtney Fuller, Linda Fletcher, Stephane Wong, Peter Maslak, Jorge Cortes, Rosemary Mazanet, Susan Branford, Timothy Hughes, Chad Galderisi, Michael Heinrich, Brian Druker, Emmanuel Beillard

Blood (2007) 110 (11): 2939.

https://doi.org/10.1182/blood.V110.11.2939.2939

Published: 2007

Journal Articles

High-Throughput Sequence Analysis of the Tyrosine Kinome in Acute Myeloid Leukemia.

Marc Loriaux, Ross Levine, Jeffrey Tyner, Stephan Frohling, Claudia Scholl, Eric Stoffregen, Gerlinde Wernig, Heidi Erickson, Chris Eide, Roland Berger, Olivier Bernard, James Griffin, Richard Stone, Matthew Meyerson, Michael Heinrich, Michael Deininger, Gary Gilliland, Brian Druker

Blood (2007) 110 (11): 886.

https://doi.org/10.1182/blood.V110.11.886.886

Published: 2007

Journal Articles

In Chronic Lymphocytic Leukemia, Zap70 Identifies a Survival Pathway Signal Cascade Involving p85 PI-3-Kinase, CrkL, and Cbl with Syk En Route to JNK1 and bcl-2.

Amy D. Hartman, MS, Annique Wilson-Weekes, MS, Larry D. Cripe, MD, Brydon Bennett, PhD, Glenn Friedman, PhD, Peter Worland, PhD, Brian Druker, MD, Shuyue Ren, PhD, Tomasz Skorski, PhD, H. Scott Boswell, MD

Blood (2006) 108 (11): 584.

https://doi.org/10.1182/blood.V108.11.584.584

Published: 2006

Journal Articles

Therapeutic Drug Monitoring of Imatinib and Impact on Clinical Decision Making.

Carolyn Blasdel, MA, RN, FNP, Yanfeng Wang, PhD, Theodore Lagattuta, BS, Brian Druker, MD, Laurie Letvak, MD, Merrill Egorin, MD FACP

Blood (2006) 108 (11): 4820.

https://doi.org/10.1182/blood.V108.11.4820.4820

Published: 2006

Journal Articles

Orally Active Inhibitors of the Imatinib Resistant Bcr-Abl Mutant T315I.

Blood (2006) 108 (11): 2180.

https://doi.org/10.1182/blood.V108.11.2180.2180

Published: 2006

Journal Articles

Preliminary Results from a Phase 2 Trial of AG-858, an Autologous Heat Shock Protein-Peptide Vaccine, in Combination with Imatinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant to Prior Imatinib Monotherapy.

David Marin, MD, Michael Mauro, MD, John Goldman, MD, Brian Druker, MD, Steven Devine, MD, Richard E. Clark, MD, Ronald Paquette, MD, Asad Bashey, MD, Martin S. Tallman, MD, April Dovholuk, Axel Hoos, MD, PhD, Pramod Srivastava, PhD

Blood (2005) 106 (11): 1094.

https://doi.org/10.1182/blood.V106.11.1094.1094

Published: 2005

Journal Articles

Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP).

Francois Guilhot, MD, Lydia Roy, MD, Joelle Guilhot, BS, Tillmann Krahnke, BSR, Agnes Guerci, MD, Brian Druker, MD, Richard Larson, MD, Steve O’Brien, MD, Charlene So, PharmD, Giorgio Massimini, MD

Blood (2005) 106 (11): 165.

https://doi.org/10.1182/blood.V106.11.165.165

Published: 2005

Journal Articles

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

Blood (2005) 106 (10): 3377–3379.

https://doi.org/10.1182/blood-2005-05-1898

Published: 2005

Journal Articles

Various Mechanisms Underlie Cytogenetic Refractoriness to Imatinib.

Lucy Crossman, Michael Heinrich, Richard Press, Stephanie Willis, Michael Deininger, Brian Druker

Blood (2004) 104 (11): 2091.

https://doi.org/10.1182/blood.V104.11.2091.2091

Published: 2004

Journal Articles

TEL/PDGFβR Induces Hematologic Malignancies in Mice That Respond to a Specific Tyrosine Kinase Inhibitor

Michael H. Tomasson, Ifor R. Williams, Robert Hasserjian, Chirayu Udomsakdi, Shannon M. McGrath, Juerg Schwaller, Brian Druker, D. Gary Gilliland

Blood (1999) 93 (5): 1707–1714.

https://doi.org/10.1182/blood.V93.5.1707

Published: 1999

NARROW

Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment

An MMR Control RNA for Reliable Monitoring of BCR-ABL Transcripts in Treated CML Patients.

High-Throughput Sequence Analysis of the Tyrosine Kinome in Acute Myeloid Leukemia.

In Chronic Lymphocytic Leukemia, Zap70 Identifies a Survival Pathway Signal Cascade Involving p85 PI-3-Kinase, CrkL, and Cbl with Syk En Route to JNK1 and bcl-2.

Therapeutic Drug Monitoring of Imatinib and Impact on Clinical Decision Making.

Orally Active Inhibitors of the Imatinib Resistant Bcr-Abl Mutant T315I.

Preliminary Results from a Phase 2 Trial of AG-858, an Autologous Heat Shock Protein-Peptide Vaccine, in Combination with Imatinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant to Prior Imatinib Monotherapy.

Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP).

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

Various Mechanisms Underlie Cytogenetic Refractoriness to Imatinib.

TEL/PDGFβR Induces Hematologic Malignancies in Mice That Respond to a Specific Tyrosine Kinase Inhibitor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only